All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubLymphoma HubMDS HubMPN Hub

Access and future prospects of advanced immunotherapies for multiple myeloma in Europe

During the 4th European CAR T-cell Meeting, the Multiple Myeloma Hub was pleased to speak with Michel Delforge, UZ Leuven, Leuven, BE. We asked, What are the future prospects and access to advanced immunotherapies for multiple myeloma (MM) in Europe?

Access and future prospects of advanced immunotherapies for multiple myeloma in Europe

In this video, Delforge explains the current treatment options for advanced refractory MM, comparing anti-BCMA CAR-T therapy with bispecific antibody therapy. Delforge also mentions both ciltacabtagene autoleucel (cilta-cel) and the CARTITUDE-1 trial (NCT03548207), and idecabtagene vicleucel (ide-cel) and the KarMMa trial (NCT03361748). Delforge highlights the importance of patient responses and overall survival rates, as well as considering the limited access to anti-BCMA CAR-T cells as an area of unmet patient need.

 

Share: